Results 121 to 130 of about 2,544 (153)

Enhancing the intracellular delivery of antisense oligonucleotides (ASO) : a comparative study of aptamer, vitamin E, and cholesterol ASO conjugates. [PDF]

RSC Adv
Balachandran AA, Poudel BH, Rahimizadeh K, Chikkanna A, Veedu RN.   +4 more
europepmc   +1 more source

Aptamers and aptamer-drug conjugates as synthetic immune modulators for cancer immunotherapy. [PDF]

Front Immunol
Arshad F, Chinnappan R, Mir TA, Ahmed Z, Arora I, Khan MI, Yaqinuddin A.   +6 more
europepmc   +1 more source

DNA Nanotechnology-Enabled Precise Regulation of Nanozymes and Their Applications. [PDF]

Research (Wash D C)
Liu Z, Zhao Y, Chen H, Fu X, Fan J, Lu L, Lyu Z, Cai H, Wang Z, Zhang C, Xiao F, Xiao Y.   +11 more
europepmc   +1 more source

Synthetic short RNA in cancer. [PDF]

Front Oncol
Tomita T, Minagawa K, Hiratsuka S.
europepmc   +1 more source

Nucleolin perturbation alters membrane lipid homeostasis.

Mol Omics
Zahavi EE, Rishal I, Oses-Prieto JA, Brandis A, Malitsky S, Itkin M, Pokorná Š, Cabrera-Cabrera F, Seeba NN, Risti R, Lõokene A, Futerman AH, Burlingame AL, Fainzilber M, Koppel I.   +14 more
europepmc   +1 more source

Programmable DNAzyme nanocatalysts orchestrate redox-immune coupling for time-gated cancer immunomodulation. [PDF]

J Nanobiotechnology
Wang L, Luo R, Zou L, Liu X, Tang Z, Dong F, Wang Z, Lyu J, Zhang Y.   +8 more
europepmc   +1 more source

Dual-Mode Aptamer AP1-F Achieves Molecular-Morphological Precision in Cancer Diagnostics via Membrane NCL Targeting. [PDF]

Curr Issues Mol Biol
Yang Z, Wang L, Xiao C, Shen X.
europepmc   +1 more source

The emerging role of aptamers in targeted cancer immunotherapy. [PDF]

Mol Ther Oncol
Zhu S, Xu R, Xu H, Wang Y, Wang L, He N, Wang HH, Ren X.   +7 more
europepmc   +1 more source

Aptamer-Nanoconjugates as Potential Theranostics in Major Neuro-Oncological and Neurodegenerative Disorders. [PDF]

Pharmaceutics
Tauser RG, Lupascu FG, Profire BS, Iacob AT, Vasincu IM, Apotrosoaei M, Chirliu OM, Lupascu D, Profire L.   +8 more
europepmc   +1 more source